The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting
Abstract
OBJECTIVE: To evaluate the safety and efficacy of aprepitant in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). DATA SOURCES: MEDLINE and PubMed database searches were conducted from 1966 to May 2004 using the following search terms: aprepitant, Emend, substance P, neurokinin-1, chemotherapy, nausea, vomiting, L-754,030, and MK-869. STUDY SELECTION AND DATA EXTRACTION: Large, randomized Phase II and III clinical trials examining the use of aprepitant for CINV, as well as all published drug interaction studies with aprepitant, were included and reviewed. Data lacking in published trials were supplemented with the manufacturer product information. DATA SYNTHESIS: The pharmacokinetics of aprepitant are favorable for once-daily oral dosing. Based on the results of published clinical trials, aprepitant appears to augment the effects of corticosteroids and 5-HT 3 antagonists when given prior to highly emetogenic chemotherapy, including cisplatin. Aprepitant appears to have the most benefit in the prevention of delayed CINV and in preventing emesis rather than nausea. Data in pediatric patients, patients undergoing stem-cell transplantation, and those receiving multiple-day or moderately emetogenic chemotherapy are lacking. Common adverse effects are limited to hiccups, asthenia, and diarrhea. More serious but rare adverse effects include neutropenia. Because aprepitant is a CYP3A4 substrate, a 3A4 inhibitor and inducer, and a 2C9 inducer, close monitoring for drug interactions is warranted. CONCLUSIONS: Triple antiemetic therapy with aprepitant, a corticosteroid, and a 5-HT 3 antagonist appears to provide improved efficacy in the prevention of emesis in patients receiving highly emetogenic chemotherapy. Due to its novel mechanism of action and demonstrated efficacy in this combination, aprepitant should be considered for formulary addition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aprepitant is a relatively new (approved 2003) substance P/neurokinin 1 receptor (NK1) highly selective, high‐affinity antagonist antiemetic agent.”
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
On the receiving end—patient perception of the side-effects of cancer chemotherapy
Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., & Tattersall, M. H. N. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90418-2 · Cited by 997
Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., Chawla, S. P., Carides, A. D., Ianus, J., Elmer, M. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.095 · Cited by 779
The distribution of substance P and 5‐hydroxytryptamine in the central nervous system of the dog
Amin, A. H., Crawford, T. B. B., & Gaddum, J. H. (1954) · The Journal of Physiology · doi:10.1113/jphysiol.1954.sp005229 · Cited by 704
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D., Harker, G., Aapro, M. S., Gandara, D., & Lindley, C. M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.103 · Cited by 605
Poli‐Bigelli, S., Rodrigues‐Pereira, J., Carides, A. D., Julie Ma, G., Eldridge, K., Hipple, A., Evans, J. K., Horgan, K. J., Lawson, F., & On behalf of the Aprepitant Protocol 054 Study Group (2003) · Cancer · doi:10.1002/cncr.11433 · Cited by 564
Gralla, R., Lichinitser, M., Van der Vegt, S., Sleeboom, H., Mezger, J., Peschel, C., Tonini, G., Labianca, R., Macciocchi, A., & Aapro, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg417 · Cited by 467
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
de Boer-Dennert, M., de Wit, R., Schmitz, P., Djontono, J., v Beurden, V, Stoter, G., & Verweij, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.507 · Cited by 378
Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
Navari, R. M., Reinhardt, R. R., Gralla, R. J., Kris, M. G., Hesketh, P. J., Khojasteh, A., Kindler, H., Grote, T. H., Pendergrass, K., Grunberg, S. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400304 · Cited by 370
Research works printed but not linked: 7
- Grunberg SM, 2004, J Support Oncol, 2, 1
- Dibble SL, 2004, Oncol Nurs For, 31, 1
- 10.1002/1097-0142(19931001)72:7<2239::AID-CNCR2820720729>3.0.CO;2-5 · doi:10.1002/1097-0142(19931001)72:7<2239::aid-cncr2820720729>3.0.co;2-5
- 10.1200/jco.2004.22.90140.2094 · doi:10.1200/jco.2004.22.90140.2094
- 2004, 2004 Redbook
- 2003, Product information. Aloxi (palonosetron)
- 10.1200/jco.2004.22.90140.8262 · doi:10.1200/jco.2004.22.90140.8262
Cited by
Aapro, M. S., Grunberg, S. M., Manikhas, G. M., Olivares, G., Suarez, T., Tjulandin, S. A., Bertoli, L. F., Yunus, F., Morrica, B., Lordick, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl137 · Cited by 338
“Serotonin antagonists are believed to be effective in acute CINV because serotonin is released rapidly from the enterochromaffin cells in the gastrointestinal tract in the first 24 h [32, 33].”
BackgroundItch: From mechanism to (novel) therapeutic approaches
Yosipovitch, G., Rosen, J. D., & Hashimoto, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.005 · Cited by 343
“The NK-1 inhibitor aprepitant demonstrated efficacy in the treatment of prurigo nodularis, Sezary syndrome, and paraneoplastic itch; however, interactions with other medications restrict its use in some patients.(132,149) In a phase II clinical trial, serlopitant, another NK-1 inhibitor, significantly reduced pruritus…”
BackgroundJordan, K., Gralla, R., Jahn, F., & Molassiotis, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.073 · Cited by 192
Andersson, K.-E., Chapple, C. R., Cardozo, L., Cruz, F., Hashim, H., Michel, M. C., Tannenbaum, C., & Wein, A. J. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832ce8a4 · Cited by 178
Update and new trends in antiemetic therapy: the continuing need for novel therapies
Feyer, P. C., & Jordan, K. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq600 · Cited by 143
Metadata
- Authors
- Massaro, A. M., & Lenz, K. L.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Lenz, Kristi L
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 39
- Issue
- 1
- Pages
- 77-85
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2163903618
- Cited by
- 73
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2015: 2 · 2014: 5 · 2013: 2 · 2012: 4
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- aprepitant, chemotherapy-induced nausea and vomiting, antiemetic therapy, highly emetogenic chemotherapy, cisplatin, substance P, NK1 receptor antagonists, pharmacokinetics, drug interactions, CYP3A4, corticosteroids, 5-HT3 receptor antagonists, adverse effects, neutropenia, drug formulary
- MeSH terms
- Aprepitant, Antiemetics, Antineoplastic Agents, Drug Interactions, Humans, Morpholines, Nausea, Patient Education as Topic, Vomiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting. https://app.cochat.ai/papers/10.1345/aph.1e242
- The paper
- Massaro, A. M., & Lenz, K. L. (2005). Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1e242
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
